Approval · Notice of Compliance 30267 · 2023
RETEVMO: Notice of Compliance 30267
Issued March 3, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30267
- Date
- March 3, 2023
- Company
- Loxo Oncology Inc
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RETEVMO | Not yet assigned | — |
Medicinal ingredients
- SELPERCATINIB 40 MG per CAP
- SELPERCATINIB 80 MG per CAP